176 related articles for article (PubMed ID: 38186580)
1. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
3. Immune infiltration and clinical significance analyses of the cancer-associated fibroblast-related signature in skin cutaneous melanoma.
Cen X; Li M; Yao A; Zheng Y; Lai W
J Gene Med; 2024 Jan; 26(1):e3614. PubMed ID: 37847069
[TBL] [Abstract][Full Text] [Related]
4. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
6. Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma.
Fan Y; Liang X; Yu D
Aging (Albany NY); 2021 Oct; 13(19):23036-23071. PubMed ID: 34613934
[TBL] [Abstract][Full Text] [Related]
7. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment.
Xue XM; Liu YY; Chen XM; Tao BY; Liu P; Zhou HW; Zhang C; Wang L; Jiang YK; Ding ZW; Shen WD; Zhang J; Yang SM; Wang FY
Front Pharmacol; 2022; 13():1064032. PubMed ID: 36569293
[No Abstract] [Full Text] [Related]
9. Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
Sun S; Deng M; Wen J; Chen X; Xu J; Liu Y; Wan H; Wang J; Yan L; He Y; Xu Y
BMC Cancer; 2023 Mar; 23(1):292. PubMed ID: 37004045
[TBL] [Abstract][Full Text] [Related]
10. Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Zhao Z; Zhang X; Xu L; Liu T; Yu S
J Immunother; 2022 Jul-Aug 01; 45(6):274-283. PubMed ID: 35543550
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
Li H; Sun X; Zhao Y; Zhang C; Jiang K; Ren J; Xing L; He M
BMC Cancer; 2023 Jun; 23(1):528. PubMed ID: 37296415
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.
Lv Y; Yuan CH; Han LY; Huang GR; Ju LC; Chen LH; Han HY; Zhang C; Zeng LH
Dis Markers; 2022; 2022():4091978. PubMed ID: 35607442
[TBL] [Abstract][Full Text] [Related]
14. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
15. Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma.
Long S; Xu J; Huang H
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2427-2447. PubMed ID: 37086280
[TBL] [Abstract][Full Text] [Related]
16. MMP2 is a immunotherapy related biomarker and correlated with cancer-associated fibroblasts infiltrate in melanoma.
Peng K; Zhang Y; Liu D; Chen J
Cancer Cell Int; 2023 Feb; 23(1):26. PubMed ID: 36788565
[TBL] [Abstract][Full Text] [Related]
17. A promising anoikis-related prognostic signature predicts prognosis of skin cutaneous melanoma.
Yue Z; Wang D; Li X
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17757-17770. PubMed ID: 37930439
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
19. Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.
Zhu Y; Song B; Yang Z; Peng Y; Cui Z; Chen L; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17897-17919. PubMed ID: 37955686
[TBL] [Abstract][Full Text] [Related]
20. A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors.
Ding Q; Li R; Wang Q; Yu L; Zi F
Front Oncol; 2023; 13():1049147. PubMed ID: 38053661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
